Here are the 10-K annual reports from Vycor Medical Inc (VYCO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VYCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYCO filings page.
Vycor Medical, Inc. reports full-year 2025 results and highlights significant going concern risks. Total revenue reached $1,863,400, up from 2024, driven mainly by Vycor Medical product sales of $1,796,070, an 18% increase. Consolidated gross profit was $1,561,107, with Vycor Medical posting an 83% gross margin and NovaVision 93%.
The company recorded a modest net loss of $72,426, but after $324,370 of cumulative preferred dividends on Series D stock, net loss available to common stockholders was $396,796. Cash was only $86,982 at December 31, 2025, against a working capital deficiency of $4,218,046, including $3,658,382 of related-party liabilities. Auditors and management state these factors raise substantial doubt about Vycor’s ability to continue as a going concern.